Immunoscintigraphy with super(131)I-labelled monoclonal antibodies HMFG sub(2) and HMFG sub(1) F(ab') sub(2) versus abdominal CT scan in the detection of residual disease in ovarian cancer patients

super(131)I-labelled HMFG sub(2) or HMFG sub(1) F(ab') sub(2) monoclonal antibody (MAb) was administered intraperitoneally to 15 patients with epithelial ovarian cancer who had completed chemotherapy and were in complete or good partial remission. Each patient received 2-3 mCi. Patients were scanned immediately after and until 7 days post-injection. In 3/15 patients the immunoscan failed because extensive adhesions from the previous surgery prevented MAb diffusion. Of the remaining 12 patients, 9 underwent second-look laparotomy (SL). Immunoscan was true positive in 8/9 (89%) patients and equivocal in 1/9 (11%), whereas the abdominal CT scan gave true positive results in 6/9 (67%) patients.